Amgen's Repatha gets a thumbs-down from U.K. cost-effectiveness watchdogs

Amgen ($AMGN) got a thumbs-down from U.K. cost watchdog the National Institute for Health and Care Excellence (NICE) for its PCSK9 cholesterol-fighter Repatha (evolocumab), bad news for the drug as it contends with pricing pushback and competes head-to-head with Sanofi ($SNY) and Regeneron's ($REGN) Praluent for market share. More from FiercePharma